As the Australian market faces a turbulent start to the week, influenced by global economic tensions and significant movements in currency and commodities, investors are keenly observing how these factors might impact local equities. In such volatile conditions, identifying stocks that may be trading below their fair value can present unique opportunities for those looking to navigate this uncertain landscape with a focus on potential long-term gains.

Top 10 Undervalued Stocks Based On Cash Flows In Australia

Name Current Price Fair Value (Est) Discount (Est) Telix Pharmaceuticals (ASX:TLX) A$10.61 A$18.69 43.2% Smart Parking (ASX:SPZ) A$1.245 A$2.25 44.7% Ramelius Resources (ASX:RMS) A$4.83 A$8.71 44.5% LGI (ASX:LGI) A$4.04 A$7.77 48% Kogan.com (ASX:KGN) A$3.82 A$6.98 45.3% Guzman y Gomez (ASX:GYG) A$21.89 A$39.09 44% Galan Lithium (ASX:GLN) A$0.455 A$0.83 45.1% DroneShield (ASX:DRO) A$4.32 A$8.21 47.4% Cromwell Property Group (ASX:CMW) A$0.44 A$0.85 48.2% Advanced Braking Technology (ASX:ABV) A$0.135 A$0.25 45.9%

Click here to see the full list of 36 stocks from our Undervalued ASX Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Galan Lithium

Overview: Galan Lithium Limited focuses on the exploration, evaluation, and development of lithium properties and has a market cap of A$523.72 million.

Operations: Galan Lithium Limited's revenue segments are currently not specified in monetary terms.

Estimated Discount To Fair Value: 45.1%

Galan Lithium's stock is trading at A$0.46, significantly below its estimated future cash flow value of A$0.83, indicating it may be undervalued based on cash flows. Despite past shareholder dilution and minimal current revenue (A$6K), the company is expected to experience substantial revenue growth of 73.1% annually and become profitable within three years, outpacing the Australian market's average growth rate. Recent presentations highlight ongoing investor engagement efforts.

Our expertly prepared growth report on Galan Lithium implies its future financial outlook may be stronger than recent results. Take a closer look at Galan Lithium's balance sheet health here in our report.ASX:GLN Discounted Cash Flow as at Jan 2026

PolyNovo

Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices across several countries including Australia and the United States, with a market cap of A$770.29 million.

Operations: The company generates revenue of A$128.70 million from the development, manufacturing, and commercialization of its NovoSorb technology.

Estimated Discount To Fair Value: 30.8%

PolyNovo's stock, trading at A$1.12, is considerably below its estimated future cash flow value of A$1.61, highlighting potential undervaluation based on cash flows. The company has demonstrated robust earnings growth of 151.2% over the past year and is projected to continue outperforming the Australian market with annual earnings growth of 27.7%. Recent executive changes include appointing Amy Demediuk as Company Secretary and General Counsel, potentially strengthening legal and strategic capabilities.

Story Continues

In light of our recent growth report, it seems possible that PolyNovo's financial performance will exceed current levels. Get an in-depth perspective on PolyNovo's balance sheet by reading our health report here.ASX:PNV Discounted Cash Flow as at Jan 2026

Telix Pharmaceuticals

Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$3.59 billion.

Operations: The company's revenue segments include Therapeutics ($7.29 million), Precision Medicine ($575.13 million), and Manufacturing Solutions ($115.57 million).

Estimated Discount To Fair Value: 43.2%

Telix Pharmaceuticals, trading at A$10.61, is significantly below its estimated future cash flow value of A$18.69, suggesting undervaluation based on cash flows. The company's earnings are forecast to grow substantially at 43% annually over the next three years, outpacing the Australian market's growth rate. However, recent profit margins have declined from 7.6% to 1.6%. Recent product advancements in prostate cancer imaging and therapy may bolster future financial performance and strategic positioning in key markets like China and the U.S.

The growth report we've compiled suggests that Telix Pharmaceuticals' future prospects could be on the up. Click here to discover the nuances of Telix Pharmaceuticals with our detailed financial health report.ASX:TLX Discounted Cash Flow as at Jan 2026

Key Takeaways

Delve into our full catalog of 36 Undervalued ASX Stocks Based On Cash Flows here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Interested In Other Possibilities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:GLN ASX:PNV and ASX:TLX.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments